The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review

Milosavljevic, Jovana; Milosavljević, Mirjana; Arsenijevic, Petar; Milentijević, Milica N; Stefanović, Sofija

doi:10.1080/13651501.2021.1872647

Cited by 11 publications

(11 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the need of supporting mental health of women who intend to undergo IVF, different types of strategies were tested. The use of Selective Serotonin Reuptake Inhibitors (SSRIs) is advisable in women scheduled for IVF and suffering from clinically significant anxiety and depression to increase the probability of achieving pregnancy 42 . Short-term high dose (3 mg/day) melatonin failed to ameliorate sleep quality in women beginning IVF, but it contributed to improve the oocyte and embryo quality 43 .…”

Section: Discussionmentioning

confidence: 99%

Women’s quality of sleep and in vitro fertilization success

Reschini

Buoli

Facchin

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Women undergoing in vitro fertilization (IVF) are emotionally challenged. Anxiety, depression, and sleep disturbances are common complaints. The impact of these symptoms on IVF outcome is however debated. In this study, we aimed at investigating whether sleep quality and psychological health can affect the chances of success of the procedure. Women undergoing IVF were recruited at the time of oocytes retrieval. Women’s sleep quality and psychological health was assessed using the Pittsburgh Sleep Quality Index (PSQI), the Fertility Problem Inventory (FPI), and the Hospital Anxiety and Depression Scale (HADS). Baseline characteristics and results of the three scales were compared between women who did and did not succeed. Overall, 263 women were included, of whom 81 had a clinical pregnancy (31%). As expected, successful women were younger, and their ovarian reserve was more preserved. FPI and HADS scores did not differ. Conversely, a statistically significant difference emerged for the PSQI score, the median [interquartile range] in pregnant and non-pregnant women being 4 [3–5] and 5 [3–7], respectively (p = 0.004). The crude and adjusted OR of pregnancy in women with a PSQI > 5 (indicating impaired sleep quality) was 0.46 (95% CI 0.25–0.86, p = 0.02) and 0.50 (95% CI: 0.26–0.94, p = 0.03), respectively. In conclusion, low sleep quality is common in women scheduled for IVF and could influence the success of the procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Women’s quality of sleep and in vitro fertilization success

Reschini

Buoli

Facchin

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These data are difficult to compare with ours because in addition to the fact that these were human studies, the duration of treatment was also quite different and corresponded more to chronic exposure than to acute exposure as in our case. However, SSRI antidepressants have not been completely free of some negative effects on male fertility [ 15 , 43 , 49 , 50 ]. Specifically, paroxetine has been shown to be associated with negative side effects, one of which is impaired gametogenesis and fertility, a point we confirm here in our animal model.…”

Section: Discussionmentioning

confidence: 99%

Paroxetine treatment in an animal model of depression improves sperm quality

et al. 2022

View full text Add to dashboard Cite

Depression in mammals is known to be associated with poor reproductive capacity. In males, it has been associated with decreased efficiency of spermatogenesis as well as the production of spermatozoa of reduced structural and functional integrity. Although antidepressants are effective in correcting depressive states, there is controversy regarding their effectiveness in restoring male reproductive function. Here, using an animal model of depression induced by a forced swim test, we confirmed that depression is accompanied by impaired male reproductive function. We further show that administration of a conventional antidepressant of the serotonin reuptake inhibitor class (paroxetine) impairs male reproductive performance in terms of sperm production and quality when administered to healthy animals. Intriguingly, when paroxetine is administered to "depressed" animals, it resulted in a complete restoration of the animal’s ability to produce sperm that appears to be as capable of meeting the parameters evaluated here as those of control animals. The one-carbon cycle (1CC) is one of the most important metabolic cycles that include the methionine and folate cycles and plays a major role in DNA synthesis, amino acids, and also the production of antioxidants. Our results show that depression affects the main components of this cycle and paroxetine on healthy mice increases homocysteine levels, decreases glycine and vitamin B12, while in depressed mice, it increases folate levels and decreases vitamin B12. Thus, paroxetine exerts negative impacts on male reproductive function when administered to healthy animals and it well correlate with the altered sperm parameters and functions of depressed animals, and its mechanism remains to be explored.

show abstract

“…Benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs) have been reported to cause hyperprolactinemia, which may cause hypogonadotropic hypogonadism and lower testosterone levels [77]. Animal and human studies have shown a worsening in sperm parameters using SSRIs [78]. In particular, some human studies have underlined an association between sperm DNA fragmentation and SSRI use: in a randomized, single-blind trial examining 60 men treated with Sertraline or behavioral therapy for 3 months, DNA fragmentation significantly increased in the treatment group, while sperm concentration and normal morphology decreased [79].…”

Section: Gonadotoxicity Of Symptomatic and Supporting Therapiesmentioning

confidence: 99%

Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research

Massarotti

Sbragia

Gazzo

et al. 2021

JCM

View full text Add to dashboard Cite

Multiple sclerosis is a chronic disease that may lead to different types of symptoms and disabilities. with the better quality of life and decreased disability due to early diagnosis and the availability of disease-modifying therapies (DMTs), the treating physician is increasingly asked to counsel patients on its effects on fertility and reproduction. In particular, reproductive issues are still scarcely studied and discussed in men. Among the still open questions are the following: (a) Does multiple sclerosis cause infertility per sè? (b) Is multiple sclerosis correlated with conditions that increase the risk of infertility? (c) Do DMTs or other therapies for multiple sclerosis impact gonadal function in men? The aim of this review is to provide an overview on the available literature data about the reproductive issues unique to men with multiple sclerosis, underlining the numerous areas where evidence is lacking and, therefore, the priorities for future research.

show abstract

The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review

Cited by 11 publications

References 52 publications

Women’s quality of sleep and in vitro fertilization success

Women’s quality of sleep and in vitro fertilization success

Paroxetine treatment in an animal model of depression improves sperm quality

Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research

Contact Info

Product

Resources

About